Respira Therapeutics

Respira Therapeutics, founded in 2013 and based in Albuquerque, New Mexico, is a private, clinical-stage biotech focused on innovative inhaled drug delivery. The company's core technology platform combines specialized particle formulation with proprietary devices to target the deep lung, aiming to improve therapeutic outcomes for serious respiratory and cardiovascular conditions. Its lead candidate, RT234-PAH, is in Phase 2B trials for the acute relief of PAH symptoms, positioning the company in a significant unmet medical need. Respira operates as a pre-revenue, platform-based therapeutics company advancing a targeted pipeline.

Integrated platform combining advanced particle engineering for deep lung deposition with proprietary inhalation device technology.

Competes in the PAH market dominated by large pharma companies (Johnson & Johnson, Bayer, United Therapeutics) offering chronic therapies. Differentiation lies in the 'as-needed' use and deep lung delivery approach, which is novel. Potential competition from other biotechs developing inhaled or acute therapies for PAH.